Roche announced today that the FDA has approved Xolair® (omalizumab) for the reduction of allergic reactions, including anaphylaxis, that may occur with accidental exposure to one or more foods in adult and paediatric patients aged 1 year and older with…
Professor Yasmine Belkaid is a renowned scientist whose research focuses on the relationship between microbes and the immune system. Her varied scientific career, which began at the Institut Pasteur with a PhD in Immunology, has covered fields including parasitology, microbiology,…
Synthekine Inc., an engineered cytokine therapeutics company, today announced a worldwide collaboration with Sanofi to develop and commercialize IL-10 receptor agonists for the treatment of inflammatory diseases. The collaboration will focus on advancing Synthekine’s multiple approaches to optimizing IL-10, with…
Takeda and The New York Academy of Sciences today announced the winners of the 2024 Innovators in Science Award for their excellence in, and commitment to, innovative science that has significantly advanced the field of research in cancer immunology. Each…
Eli Lilly and Company announced today that the U.S. FDA has approved Omvoh™ (mirikizumab-mrkz) infusion (300 mg/15 mL)/injection (100 mg/mL), the first and only interleukin-23p19 (IL-23p19) antagonist for the treatment of moderately to severely active ulcerative colitis (UC) in adults.…
Sanofi and Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd., announce today a collaboration to co-develop and co-commercialize asset TEV’574, currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn’s Disease, two types of…